A deeper understanding of the interplay between FDX1 and cuproptosis may foster the development of more effective and safer anti-tumor therapies, particularly for challenging malignancies where cuproptosis mechanisms could offer novel treatment options. This evidence concerns the gene FDX1 and neoplasm.